First Time Loading...

Immunoprecise Antibodies Ltd
XTSX:IPA

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
XTSX:IPA
Watchlist
Price: 6.5 CAD 0.78% Market Closed
Updated: Jun 4, 2024

Immunoprecise Antibodies Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immunoprecise Antibodies Ltd
Total Liabilities & Equity Peer Comparison

Comparables:
ABCL
ARCH
RP
IOT

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Immunoprecise Antibodies Ltd
XTSX:IPA
Total Liabilities & Equity
CA$67m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Total Liabilities & Equity
$1.5B
CAGR 3-Years
14%
CAGR 5-Years
133%
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Total Liabilities & Equity
CA$636.5k
CAGR 3-Years
-5%
CAGR 5-Years
11%
CAGR 10-Years
32%
Replicel Life Sciences Inc
XTSX:RP
Total Liabilities & Equity
CA$331.5k
CAGR 3-Years
-5%
CAGR 5-Years
23%
CAGR 10-Years
-20%
Innovotech Inc
XTSX:IOT
Total Liabilities & Equity
CA$1.1m
CAGR 3-Years
5%
CAGR 5-Years
33%
CAGR 10-Years
12%

See Also

What is Immunoprecise Antibodies Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
67m CAD

Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Total Liabilities & Equity amounts to 67m CAD.

What is Immunoprecise Antibodies Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
40%

Over the last year, the Total Liabilities & Equity growth was 146%. The average annual Total Liabilities & Equity growth rates for Immunoprecise Antibodies Ltd have been 40% over the past three years .